157 related articles for article (PubMed ID: 21978673)
21. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41.
Zhou G; Wu D; Hermel E; Balogh E; Gochin M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1500-3. PubMed ID: 20153190
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
Yang J; Li LL; Li JR; Yang JX; Zhang F; Chen G; Yu R; Ouyang WJ; Wu SW
Bioorg Med Chem Lett; 2018 Jan; 28(1):49-52. PubMed ID: 29162455
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.
Liu K; Lu H; Hou L; Qi Z; Teixeira C; Barbault F; Fan BT; Liu S; Jiang S; Xie L
J Med Chem; 2008 Dec; 51(24):7843-54. PubMed ID: 19053778
[TBL] [Abstract][Full Text] [Related]
24. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
Li W; Lu L; Li W; Jiang S
Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
[TBL] [Abstract][Full Text] [Related]
26. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
[TBL] [Abstract][Full Text] [Related]
27. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
Liu Y; Ke Z; Wu KY; Liu S; Chen WH; Jiang S; Jiang ZH
ChemMedChem; 2011 Sep; 6(9):1654-64. PubMed ID: 21688394
[TBL] [Abstract][Full Text] [Related]
28. A mammalian two-hybrid system-based assay for small-molecular HIV fusion inhibitors targeting gp41.
Shui X; Lu X; Gao Y; Liu C; Ren F; Jiang Q; Zhang H; Zhao B; Zheng Z
Antiviral Res; 2011 Apr; 90(1):54-63. PubMed ID: 21352856
[TBL] [Abstract][Full Text] [Related]
29. A homogeneous time-resolved fluorescence assay to identify inhibitors of HIV-1 fusion.
Smeulders L; Bunkens L; Vereycken I; Van Acker K; Holemans P; Gustin E; Van Loock M; Dams G
Methods Mol Biol; 2013; 1030():11-7. PubMed ID: 23821256
[TBL] [Abstract][Full Text] [Related]
30. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
Liu S; Boyer-Chatenet L; Lu H; Jiang S
J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
[TBL] [Abstract][Full Text] [Related]
31. Systematic Evaluation of Fluorination as Modification for Peptide-Based Fusion Inhibitors against HIV-1 Infection.
Huhmann S; Nyakatura EK; Rohrhofer A; Moschner J; Schmidt B; Eichler J; Roth C; Koksch B
Chembiochem; 2021 Dec; 22(24):3443-3451. PubMed ID: 34605595
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
Yi HA; Fochtman BC; Rizzo RC; Jacobs A
Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
[TBL] [Abstract][Full Text] [Related]
33. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S
Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560
[TBL] [Abstract][Full Text] [Related]
34. Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).
Zhang D; Li W; Jiang S
Expert Opin Ther Pat; 2015 Feb; 25(2):159-73. PubMed ID: 25428639
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 Entry Inhibitors: A Review of Experimental and Computational Studies.
Mostashari Rad T; Saghaie L; Fassihi A
Chem Biodivers; 2018 Oct; 15(10):e1800159. PubMed ID: 30027572
[TBL] [Abstract][Full Text] [Related]
36. Making strides in peptide-based therapeutics.
Guarracino DA; Arora PS
Chem Biol; 2009 Sep; 16(9):919-20. PubMed ID: 19778718
[TBL] [Abstract][Full Text] [Related]
37. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
38. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1.
Debnath AK; Radigan L; Jiang S
J Med Chem; 1999 Aug; 42(17):3203-9. PubMed ID: 10464007
[TBL] [Abstract][Full Text] [Related]
39. [Design, synthesis and activity assessment of aryl-substituent benzyl acid targeting HIV gp41].
Wang H; Chen Z; Qiu J; Yu X; Xie Y; Liu S
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):221-4. PubMed ID: 23443776
[TBL] [Abstract][Full Text] [Related]
40. Current peptide HIV type-1 fusion inhibitors.
Pang W; Tam SC; Zheng YT
Antivir Chem Chemother; 2009 Sep; 20(1):1-18. PubMed ID: 19794228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
